Sizing Up Pneumonia Investment

2018-04-16T16:51:39Z (GMT) by Rebecca Brown Michael Head
<p></p><p>The report, entitled ‘<b>Sizing up pneumonia research’</b> summarises public and philanthropic investment for pneumonia-related research by the G20 countries between 2000 and 2015. It provides analysis of investment trends over time, the geography of pneumonia research funding, and levels of investment in specific priority areas such as paediatric, antimicrobial resistance and vaccine-focused research. </p><p><br></p><p>Overall, $3 billion of pneumonia-related research investment is described here, covering over 2000 studies from dozens of funders. </p> <p> </p> <p>Despite the very high mortality (1 million deaths per year, mostly in children aged under 5 in resource-poor settings), the volume of research into pneumonia is low, and the ‘Big Three’ of HIV, malaria and tuberculosis all receive greater levels of funding compared to their respective burden of disease. There was also little investment specifically targeted at high-burden nations in sub-Saharan Africa and Asia. </p><p><br></p><p>Pneumonia has been historically neglected by the global health community, and that needs to change. Our analyses inform the evidence base around resource allocation and provide a platform for further multi-disciplinary stakeholder discussions including policymakers and governments, funders, researchers, advocates and clinicians.</p><br><p></p>